参考文献/References:
[1] Sacks FM,Pfeffer MA,Moye LA,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators[J]. N Engl J Med,1996,335(14):1001-1009.
[2] Jacobs D,Blackburn H,Higgins M,et al. Report of the conference on low blood cholesterol:mortality associations[J]. Circulation,1992,86(3):1046-1060.
[3] Shao JY,Lee FP,Chang CL,et al. Statin-based palliative therapy for hepatocellular carcinoma[J]. Medicine(Baltimore),2015,94(42):e1801.
[4] Wolfe AR,Debeb BG,Lacerda L,et al. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a[J]. Breast Cancer Res Treat,2015,154(3):495-508.
[5] Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[6] Kimbung S,Lettiero B,Feldt M,et al. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer[J]. Oncotarget,2016,7(37):59640-59651.
[7] Liao JK. Isoprenoids as mediators of the biological effects of statins[J]. J Clin Invest,2002,110(3):285-288.
[8] Collins R,Reith C,Emberson J,et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet,2016,388(10059):2532-2561.
[9] Liao JK,Laufs U. Pleiotropic effects of statins[J]. Annu Rev Pharmacol Toxicol,2005,45:89-118.
[10] Matusewicz L,Filip-Psurska B,Psurski M,et al. EGFR-targeted immunoliposomes as a selective delivery system of simvastatin,with potential use in treatment of triple-negative breast cancers[J]. Int J Pharm,2019,569:118605
[11] Huang SW,Chyuan IT,Shiue C,et al. Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signalling cascade[J]. J Cell Mol Med,2020,24(2):1822-1836.
[12] Kanugula AK,Dhople VM,V?lker U,et al. Fluvastatin mediated breast cancer cell death:a proteomic approach to identify differentially regulated proteins in MDA-MB-231 cells[J]. PLoS One,2014,9(9):e108890.
[13] Yin L,He Z,Yi B,et al. Simvastatin suppresses human breast cancer cell invasion by decreasing the expression of pituitary tumor-transforming gene 1[J]. Front Pharmacol, 2020 ,11:574068.
[14] Manda K,Juer? D,Fischer P,et al. Simvastatin treatment varies the radiation response of human breast cells in 2D or 3D culture[J]. Invest New Drugs,2021,39(3):658-669.
[15] Beckwitt CH,Brufsky A,Oltvai ZN,et al. Statin drugs to reduce breast cancer recurrence and mortality[J]. Breast Cancer Res,2018,20(1):144.
[16] Bytautaite M,Petrikaite V. Comparative study of lipophilic statin activity in 2D and 3D?in vitro models of human breast cancer cell lines MDA-MB-231 and MCF-7[J]. Onco Targets Ther,2020,13:13201-13209.
[17] Wang L,Wang Y,Chen A,et al. Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway[J]. FASEB J,2019,33(12):13710-13721.
[18] Ma Q,Gao Y,Xu P,et al. Atorvastatin inhibits breast cancer cells by downregulating PTEN/AKT pathway via promoting Ras homolog family member B(RhoB)[J]. Biomed Res Int,2019,2019:3235021.
[19] Ahern TP,Lash TL,Damkier P,et al. Statins and breast cancer prognosis:evidence and opportunities[J]. Lancet Oncol,2014,15(10):e461-e468.
[20] Campbell MJ,Esserman LJ,Zhou Y,et al. Breast cancer growth prevention by statins[J]. Cancer Res,2006,66(17):8707-8714.
[21] Bonovas S,Filioussi K,Tsavaris N,et al. Use of statins and breast cancer:a meta-analysis of seven randomized clinical trials and nine observational studies[J]. J Clin Oncol,2005,23(34):8606-8612.
[22] Kumar AS,Benz CC,Shim V,et al. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users[J]. Cancer Epidemiol Biomarkers Prev,2008,17(5):1028-1033.
[23] Borgquist S,Broberg P,Tojjar J,et al. Statin use and breast cancer survival—a Swedish nationwide study[J]. BMC Cancer,2019,19(1):54.
[24] Langballe R,Cronin-Fenton D,Dehlendorff C,et al. Statin use and risk of contralateral breast cancer:a nationwide cohort study[J]. Br J Cancer,2018,119(10):1297-1305.
[25] Liu B,Yi Z,Guan X,et al. The relationship between statins and breast cancer prognosis varies by statin type and exposure time:a meta-analysis[J]. Breast Cancer Res Treat,2017,164(1):1-11.
[26] Wu QJ,Tu C,Li YY,et al. Statin use and breast cancer survival and risk:a systematic review and meta-analysis[J]. Oncotarget,2015,6(40):42988-43004.
[27] Manthravadi S,Shrestha A,Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer:a systematic review and meta-analysis [J]. Int J Cancer,2016,139(6):1281-1288.
[28] Zhong S,Zhang X,Chen L,et al. Statin use and mortality in cancer patients:systematic review and meta-analysis of observational studies[J]. Cancer Treat Rev,2015,41(6):554-567.
[29] Mansourian M,Haghjooy-Javanmard S,Eshraghi A,et al. Statins use and risk of breast cancer recurrence and death:a systematic review and meta-analysis of observational studies[J]. J Pharm Pharm Sci,2016,19(1):72-81.
[30] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范（2019年版）[J]. 中国癌症杂志,2019,29(8):609-680.
[31] Guan X,Liu Z,Zhao Z,et al. Emerging roles of low-density lipoprotein in the development and treatment of breast cancer[J]. Lipids Health Dis,2019,18(1):137.
[32] Kumar AS,Esserman LJ. Statins:health-promoting agents show promise for breast cancer prevention[J]. Clin Breast Cancer,2005,6(5):455-459.
[33] G?bel A,Thiele S,Browne AJ,et al. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells[J]. Cancer Lett,2016,375(1):162-171.
[34] Lacerda L,Reddy JP,Liu D,et al. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation[J]. Stem Cells Transl Med,2014,3(7):849-856.
[35] Caron J,Nohria A. Cardiac toxicity from breast cancer treatment:can we avoid this?[J]. Curr Oncol Rep ,2018,20(8):61.
[36] Acar Z,Kale A,Turgut M,et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy[J]. J Am Coll Cardiol,2011,58(9):988-989.
[37] Calvillo-Argüelles O,Abdel-Qadir H,Michalowska M,et al. Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab?therapy[J]. Can J Cardiol,2019,35(2):153-159.
[38] Ghasemi A,Ghashghai Z,Akbari J,et al. Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer:a randomized,double-blind,placebo-controlled trial[J]. Eur J Clin Pharmacol,2019,75(2):171-178.
相似文献/References:
[1]董新江 尚茹茹 刘晓红.乳腺癌放化疗引起心脏毒性的一级预防进展[J].心血管病学进展,2020,(1):78.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.021]
DONG Xinjiang,SHANG Ruru,?LIU Xiaohong.Primary Prevention of Cardiotoxicity Caused by Radiotherapy and Chemotherapy for Breast Cancer[J].Advances in Cardiovascular Diseases,2020,(9):78.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.021]
[2]布热比古力·阿布力米提 付真彦.乳腺癌药物治疗与心肌损伤[J].心血管病学进展,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
Burebiguli·abulimitiFU Zhenyan.Drug Therapy of Breast Cancer and Assosiated Myocardial Damage[J].Advances in Cardiovascular Diseases,2020,(9):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
[3]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(9):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[4]白宏晔 甘辉立.呼吸系统疾病在他汀类药物多效性中的获益[J].心血管病学进展,2022,(9):824.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.014]
BAI Hongye,GAN Huili.Benefits of Respiratory Disease in Pleiotropy of Statins[J].Advances in Cardiovascular Diseases,2022,(9):824.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.014]
[5]郭良 黄鹤.恶性肿瘤相关心房颤动发病机制的研究进展[J].心血管病学进展,2022,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
GUO LiangHUANG He.Pathogenesis of Malignant Tumor-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(9):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
[6]杨仙 陈芸霖 殷跃辉 易鑫 杨敏 崔犇.女性乳腺癌相关性心房颤动的研究现状[J].心血管病学进展,2023,(8):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]
YANG Xian,CHEN Yunlin,YIN Yuehui,et al.Research Status of Female Breast Cancer Associated Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(9):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]
[7]杜明亮 王泊然 惠慧 郑晓群.维持血液透析合并冠心病的患者降脂治疗的研究进展[J].心血管病学进展,2023,(12):1084.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.007]
DU Mingliang,WANG Boran,HUI Hui,et al.Lipid-Lowering Therapy in Maintenance Hemodialysis Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2023,(9):1084.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.007]